VJHemOnc is committed to improving our service to you

ASH 2019 | NKTR-255 in R/R MM and NHL

VJHemOnc is committed to improving our service to you

Nina Shah

Nina Shah, MD, University of California-San Francisco, San Francisco, CA, outlines a phase I, dose escalation and expansion study (NCT04136756) of NKTR-255, a polymer-conjugated IL-15, as a single agent in relapsed/refractory multiple myeloma (MM) and non-Hodgkin lymphoma (NHL), plus in combination with daratumumab as a salvage regimen for MM. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter